|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Ablynx
gptkb:Bioverativ
gptkb:Synthélabo
gptkb:Genzyme
gptkb:Aventis
gptkb:Principia_Biopharma
Translate Bio
|
|
gptkbp:CEO
|
gptkb:Paul_Hudson
|
|
gptkbp:country
|
gptkb:France
|
|
gptkbp:formedByMergerOf
|
gptkb:Sanofi-Synthélabo
gptkb:Aventis
|
|
gptkbp:founded
|
2004
|
|
gptkbp:headquarters_location
|
gptkb:Paris
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
FR0000120578
|
|
gptkbp:member
|
gptkb:Euro_Stoxx_50
gptkb:CAC_40
|
|
gptkbp:netIncome
|
€5.8 billion
|
|
gptkbp:notableProduct
|
gptkb:Aubagio
gptkb:Clexane
gptkb:Dupixent
gptkb:Fluzone
gptkb:Kevzara
gptkb:Lantus
gptkb:Menactra
gptkb:Plavix
gptkb:Praluent
gptkb:Toujeo
Polio vaccine
|
|
gptkbp:numberOfEmployees
|
over 90,000
|
|
gptkbp:officialWebsite
|
https://www.sanofi.com/
|
|
gptkbp:products
|
vaccines
pharmaceutical drugs
consumer healthcare products
|
|
gptkbp:researchInterest
|
gptkb:diabetes
immunology
oncology
vaccines
cardiovascular diseases
rare diseases
|
|
gptkbp:revenue
|
€43.1 billion
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
gptkb:Euronext_Paris
|
|
gptkbp:subsidiary
|
gptkb:Sanofi_Pasteur
gptkb:Genzyme
gptkb:Chattem
gptkb:Sanofi_India
|
|
gptkbp:bfsParent
|
gptkb:Synthélabo
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sanofi (after merger)
|